The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection
- 247 Downloads
The hypothesis that host genetics play an essential role in the ability not only to clear acute hepatitis C infection but also to achieve sustained virologic response (SVR) to interferon (IFN)-based therapy has been proved with the recent discovery of two single-nucleotide polymorphisms on chromosome 19. Variants in the minor allele rs8099917 and the proximate polymorphism rs12979860, 3 kb upstream of the interleukin (IL)-28B gene, which encodes the endogenous antiviral cytokine IFN-λ, are associated with SVR and with natural viral clearance. The disparate frequencies of these alleles in ethnic groups worldwide may well explain differing rates of SVR among them. The test for one of these polymorphisms is now commercially available and can serve as a powerful predictor of a patient’s chance of achieving SVR. Perhaps more importantly, the test can help the clinician personally tailor the duration and even the type of therapy that is most appropriate for an individual patient, newly or chronically infected with the hepatitis C virus.
KeywordsHepatitis C Acute hepatitis C Chronic hepatitis C Viral hepatitis IL-28 polymorphisms Genome-wide association studies Single-nucleotide polymorphisms
Conflicts of interest: B. Pearlman—speakers’ bureau for Merck.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6:35–47.Google Scholar
- 6.• Ge D, Fellay J, Thompson AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399–401. This landmark paper was the first to describe the polymorphism, rs12979860, near the IL-28B gene that is highly predictive of a patient’s achieving SVR, and may well become an essential component in clinical decision making regarding hepatitis C therapy. CrossRefPubMedGoogle Scholar
- 7.• Manolio TA: Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010, 363:166–176. This succinct review paper describes the technical and clinical aspects of the use of the genomewide association study and its success in identifying genetic associations with complex traits. CrossRefPubMedGoogle Scholar
- 23.• Thomas DL, Thio CL, Martin MP, et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798–801. This article describes the first study to demonstrate the IL28B polymorphism’s association with resolution of acute HCV infection among Caucasians of European ancestry and African Americans. CrossRefPubMedGoogle Scholar
- 29.• Tillman HL, Thompson AJ, Patel K, et al.: A polymorphism near IL28B is associated with spontaneous clearance, of acute hepatitis C virus and jaundice. Gastroenterology 2010 (Epub ahead of print). Using the cohort of young German women who had received contaminated immunoglobulin, the authors of this study were able to evaluate the IL-28B polymorphism in acute infection. The analysis is particularly important because it was able to study host genetics in a single-source outbreak at the time of infection where ethnic background and viral sequence diversity are minimal. Google Scholar
- 38.Urban TJ, Thompson AJ, Bradrick S, et al.: IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in chronic hepatitis C patients. Hepatology 2010 (Epub ahead of print).Google Scholar
- 41.• Thompson AJ, Muir AJ, Sulkowski MS, et al.: Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120–129. These investigators confirmed that the IL-28B polymorphism is the strongest baseline predictor of SVR in genotype 1-infected patients treated with peginterferon-ribavirin. They demonstrated that the favorable IL-28B genotype is associated with improved viral kinetics and increased rate of RVR relative to those with the unfavorable genotype. The paper is the most clinically relevant to date among the papers pertaining to chronic HCV treatment and the IL-28B polymorphism. CrossRefPubMedGoogle Scholar
- 45.Stattermayer AF, Stauber R, Hofer H, et al.: Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2010 (Epub ahead of print).Google Scholar